UNSPSC 51363201: Ethypicone

This classification denotes a sedative and hypnotic with the molecular formula C10H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2PO3M8FE7C, chemically known as 3,3-diethyl-5-methyl-2,4(1h,3h)-pyridinedione but generally known as ethypicone, which bears US NIH Compound Identifier 68842. European Medicines Agency schedules Ethypicone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07294MIG.

UNSPSC 51363201 Ethypicone, a Commodity code, does not reflect the work actually being solicited under this designation in recent state and local procurement. The three opportunities tagged with this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic pharmaceuticals and over-the-counter products—none of which are ethypicone (a pharmaceutical binding agent with limited consumer or public-health application). The code shows little relevant recent activity for the nominal product line; the mismatch between the code assignment and the solicited goods suggests tagging error or administrative misclassification rather than genuine procurement demand under this Commodity.

The recent opportunities instead reflect broader state and local pharmaceutical procurement activity across multiple issuing bodies and geographies. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the deadline year appears inconsistent with the posting date); the Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities with a response deadline of March 26, 2026. Procurement spans county health departments, state HHS agencies, and multistate cooperative purchasing vehicles, with geographic activity in Florida, Texas, Minnesota, and Oregon. Vendors pursuing work in this space should monitor pharmaceutical and controlled-substance procurement vehicles rather than rely on ethypicone-specific code tracking.